Financial News

Nicox signs agreement for ZERVIATE in South Korea

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the signature of an exclusive license agreement with Samil Pharmaceutical Co., Ltd for the development and commercialization of ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea. Samil Pharmaceutical,

Read more

Nicox Raises €12.5 Million to Advance NCX 470 into Phase 3 in Glaucoma

Not for distribution in or into the United States of America, Canada, Japan or Australia, except as permitted by applicable law                                                             

  • Initiation of the first U.S. Phase 3 clinical trial for NCX 470 planned for Q2 2020
  • Company expects to be financed to reach the top-line results from the first U.S.
Read more

Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma

  • NCX 470 0.065% produced significantly superior intraocular pressure (IOP) lowering compared with latanoprost 0.005% in secondary analyses
  • NCX 470 showed improved IOP lowering with each incremental concentration of NCX 470 tested, setting the stage for potentially further IOP lowering at a higher dose
  • Phase 3 clinical program expected to be initiated in Q2 2020 with 0.065% and 0.1% doses,
Read more
More news
Press releases
More press releases